652 related articles for article (PubMed ID: 31182537)
1. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.
Borman AM; Muller J; Walsh-Quantick J; Szekely A; Patterson Z; Palmer MD; Fraser M; Johnson EM
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182537
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method.
Borman AM; Muller J; Walsh-Quantick J; Szekely A; Patterson Z; Palmer MD; Fraser M; Johnson EM
J Antimicrob Chemother; 2020 May; 75(5):1194-1205. PubMed ID: 32025716
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
[TBL] [Abstract][Full Text] [Related]
5. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
9. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
10. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species.
Morris AJ; Rogers K; McKinney WP; Roberts SA; Freeman JT
J Glob Antimicrob Resist; 2018 Sep; 14():72-77. PubMed ID: 29486358
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
[TBL] [Abstract][Full Text] [Related]
16. Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients.
Morace G; Borghi E; Iatta R; Amato G; Andreoni S; Brigante G; Farina C; Lo Cascio G; Lombardi G; Manso E; Mussap M; Pecile P; Rigoli R; Tangorra E; Valmarin M; Montagna MT
BMC Infect Dis; 2011 May; 11():130. PubMed ID: 21586108
[TBL] [Abstract][Full Text] [Related]
17. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in
Espinel-Ingroff A; Turnidge J; Alastruey-Izquierdo A; Botterel F; Canton E; Castro C; Chen YC; Chen Y; Chryssanthou E; Dannaoui E; Garcia-Effron G; Gonzalez GM; Govender NP; Guinea J; Kidd S; Lackner M; Lass-Flörl C; Linares-Sicilia MJ; López-Soria L; Magobo R; Pelaez T; Quindós G; Rodriguez-Iglesia MA; Ruiz MA; Sánchez-Reus F; Sanguinetti M; Shields R; Szweda P; Tortorano A; Wengenack NL; Bramati S; Cavanna C; DeLuca C; Gelmi M; Grancini A; Lombardi G; Meletiadis J; Negri CE; Passera M; Peman J; Prigitano A; Sala E; Tejada M
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038
[TBL] [Abstract][Full Text] [Related]
18. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Dagi HT; Findik D; Senkeles C; Arslan U
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
[TBL] [Abstract][Full Text] [Related]
19. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
Skrodeniene E; Dambrauskiene A; Vitkauskiene A
Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
[TBL] [Abstract][Full Text] [Related]
20. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.
Minea B; Nastasa V; Moraru RF; Kolecka A; Flonta MM; Marincu I; Man A; Toma F; Lupse M; Doroftei B; Marangoci N; Pinteala M; Boekhout T; Mares M
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):367-83. PubMed ID: 25224578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
